These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18555708)

  • 1. XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy.
    Pinho MB; Costas F; Sellos J; Dienstmann R; Andrade PB; Herchenhorn D; Peixoto FA; Santos VO; Small IA; Guimarães DP; Ferreira CG
    Urol Oncol; 2009; 27(4):382-90. PubMed ID: 18555708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer.
    Kempkensteffen C; Fritzsche FR; Johannsen M; Weikert S; Hinz S; Dietel M; Riener MO; Moch H; Jung K; Krause H; Miller K; Kristiansen G
    BMC Cancer; 2009 Aug; 9():276. PubMed ID: 19664236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer.
    Huang J; Yao WY; Zhu Q; Tu SP; Yuan F; Wang HF; Zhang YP; Yuan YZ
    Cancer Sci; 2010 Feb; 101(2):559-67. PubMed ID: 19922503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma.
    Augello C; Caruso L; Maggioni M; Donadon M; Montorsi M; Santambrogio R; Torzilli G; Vaira V; Pellegrini C; Roncalli M; Coggi G; Bosari S
    BMC Cancer; 2009 Apr; 9():125. PubMed ID: 19397802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
    Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
    Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
    Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells.
    Zhao WJ; Deng BY; Wang XM; Miao Y; Wang JN
    Asian Pac J Cancer Prev; 2015; 16(6):2453-8. PubMed ID: 25824780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
    Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
    BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peculiarities of urinary bladder cancer tumor cells apoptosis response on neoadjuvant chemotherapy].
    Iatsyna AI; Stakhovskiĭ ÉA; Sheremet IaA; Spivak SI; Stakhovskiĭ AÉ; Gavriliuk ON; Vitruk IuV; Emets AI; Blium IaB
    Tsitol Genet; 2011; 45(4):3-8. PubMed ID: 21950136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
    North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
    J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
    Pouessel D; Bastuji-Garin S; Houédé N; Vordos D; Loriot Y; Chevreau C; Sevin E; Beuzeboc P; Taille A; Le Thuaut A; Allory Y; Culine S
    Clin Genitourin Cancer; 2017 Feb; 15(1):e45-e52. PubMed ID: 27554584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
    Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
    Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XAF1 is frequently methylated in human esophageal cancer.
    Chen XY; He QY; Guo MZ
    World J Gastroenterol; 2012 Jun; 18(22):2844-9. PubMed ID: 22719195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
    Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
    Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor cells.
    Hatakeyama K; Yamakawa Y; Fukuda Y; Ohshima K; Wakabayashi-Nakao K; Sakura N; Tanizawa Y; Kinugasa Y; Yamaguchi K; Terashima M; Mochizuki T
    Gastric Cancer; 2015 Oct; 18(4):751-61. PubMed ID: 25216542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
    Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
    Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.